Stifel Initiates Coverage On Janux Therapeutics with Buy Rating, Announces Price Target of $70
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino has initiated coverage on Janux Therapeutics (NASDAQ:JANX) with a Buy rating and set a price target of $70.
September 06, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel has initiated coverage on Janux Therapeutics with a Buy rating and a price target of $70, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a $70 price target by Stifel suggests a positive sentiment towards Janux Therapeutics. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100